Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.

Autor:	El Zarif T; Dana-Farber Cancer Institute, Boston, MA., Nassar AH; Yale University School of Medicine, New Haven, CT., Adib E; Dana-Farber Cancer Institute, Boston, MA.; Brigham and Women's Hospital, Boston, MA., Fitzgerald BG; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Huang J; Dana-Farber Cancer Institute, Boston, MA., Mouhieddine TH; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Rubinstein PG; Division of Hematology/Oncology, Ruth M. Rothstein CORE Center, Cook County Health and Hospital Systems (Cook County Hospital), University of Illinois Chicago Cancer Center, Chicago, IL., Nonato T; Moores Cancer Center, The University of California San Diego, La Jolla, CA., McKay RR; Moores Cancer Center, The University of California San Diego, La Jolla, CA., Li M; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Mittra A; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Owen DH; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Baiocchi RA; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Lorentsen M; Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC., Dittus C; Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC., Dizman N; Yale University School of Medicine, New Haven, CT., Falohun A; University of Texas MD Anderson Cancer Center, Houston, TX., Abdel-Wahab N; University of Texas MD Anderson Cancer Center, Houston, TX.; Assiut University Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt., Diab A; University of Texas MD Anderson Cancer Center, Houston, TX., Bankapur A; Department of Surgery, Division of Urology, Cook County Health, Chicago, IL., Reed A; Department of Surgery, Division of Urology, Cook County Health, Chicago, IL., Kim C; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Arora A; Medstar/Georgetown-Washington Hospital Center, Washington, DC., Shah NJ; Memorial Sloan Kettering Cancer Center, New York, NY., El-Am E; Indiana University School of Medicine, Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Kozaily E; Indiana University School of Medicine, Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Abdallah W; Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA., Al-Hader A; Indiana University School of Medicine, Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Abu Ghazal B; Kansas University Cancer Center, Kansas City, KS., Saeed A; Kansas University Cancer Center, Kansas City, KS.; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA., Drolen C; University of California Los Angeles, Los Angeles, CA., Lechner MG; University of California Los Angeles, Los Angeles, CA., Drakaki A; University of California Los Angeles, Los Angeles, CA., Baena J; 12 de Octubre University Hospital, Madrid, Spain., Nebhan CA; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Haykal T; Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC., Morse MA; Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC., Cortellini A; Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom.; Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy., Pinato DJ; Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom.; Department of Translational Medicine, Università Del Piemonte Orientale 'A. Avogadro', Novara, Italy., Dalla Pria A; Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom.; Chelsea and Westminster Hospital, London, United Kingdom., Hall E; University of Washington, Seattle, WA., Bakalov V; Allegheny Health Network, Pittsburgh, PA., Bahary N; Allegheny Health Network, Pittsburgh, PA., Rajkumar A; Seidman Cancer Center, University Hospitals, Cleveland, OH., Mangla A; Seidman Cancer Center, University Hospitals, Cleveland, OH., Shah V; Mayo Clinic, Phoenix, AZ., Singh P; Mayo Clinic, Phoenix, AZ., Aboubakar Nana F; Université Catholique de Louvain (UCLouvain), Brussels, Belgium., Lopetegui-Lia N; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH., Dima D; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH., Dobbs RW; Division of Hematology/Oncology, Ruth M. Rothstein CORE Center, Cook County Health and Hospital Systems (Cook County Hospital), University of Illinois Chicago Cancer Center, Chicago, IL., Funchain P; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH., Saleem R; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK., Woodford R; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Long GV; Melanoma Institute Australia, Faculty of Medicine & Health, Charles Perkins Centre, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Genova C; UO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Dipartimento di Medicina Interna e Specialità Mediche (DiMI), Università degli Studi di Genova, Genova, Italy., Barletta G; UO Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Puri S; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Florou V; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Idossa D; University of California San Francisco, San Francisco, CA., Saponara M; Division of Melanoma and Sarcoma Medical Treatment, IEO European Institute of Oncology IRCCS Milan, Milan, Italy., Queirolo P; Division of Melanoma and Sarcoma Medical Treatment, IEO European Institute of Oncology IRCCS Milan, Milan, Italy., Lamberti G; Department of Experimental, Diagnostic and Specialty Medicine, Università di Bologna, Bologna, Italy., Addeo A; Swiss Cancer Center Leman, Geneva University Hospitals, University of Geneva, Geneva, Switzerland., Bersanelli M; University Hospital of Parma, Parma, Italy., Freeman D; Dana-Farber Cancer Institute, Boston, MA., Xie W; Dana-Farber Cancer Institute, Boston, MA., Reid EG; Moores Cancer Center, The University of California San Diego, La Jolla, CA., Chiao EY; University of Texas MD Anderson Cancer Center, Houston, TX., Sharon E; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Ramaswami R; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Bower M; Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom.; Chelsea and Westminster Hospital, London, United Kingdom., Emu B; Yale University School of Medicine, New Haven, CT., Marron TU; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Choueiri TK; Dana-Farber Cancer Institute, Boston, MA., Baden LR; Brigham and Women's Hospital, Boston, MA., Lurain K; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Sonpavde GP; AdventHealth Cancer Institute, Orlando, FL., Naqash AR; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK.
Jazyk:	angličtina
Zdroj:	Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jul 20; Vol. 41 (21), pp. 3712-3723. Date of Electronic Publication: 2023 May 16.
DOI:	10.1200/JCO.22.02459
Abstrakt:	Purpose: Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. Methods: This retrospective study included PWH treated with anti-PD-1- or anti-PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). Results: Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti-PD-1/anti-PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was -0.06 months (95% CI, -5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, -4.02 to 8.48; P = .48) for OS. Conclusion: Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu